智通财经APP讯，康诺亚-B(02162)发布公告，成都康诺亚、北京诺诚健华及合营企业已与Prolium就CM355的开发及商业化订立协议。根据协议条款，Prolium将拥有在全球非肿瘤适应症以及亚洲以外地区肿瘤适应症方面开发、注册、生产及商业化CM355的独家权利。根据协议，有关付款将由成都康诺亚及北京诺诚健华平均分摊。
CM355是一种CD20×CD3双特异性抗体，通过与肿瘤细胞上的CD20和T细胞上的CD3结合，重定向并激活T细胞，从而通过T细胞介导的细胞毒性(TDCC)消灭肿瘤细胞。该双特异性抗体在肿瘤学及非肿瘤学领域都表现出了强大的潜力。目前，CM355正在进行临床试验，以评估其安全性及疗效。
根据成都康诺亚及北京诺诚健华各自在合营企业中拥有的50%权益，其将共同有权收取金额为1750万美元的首付款和近期付款、最高达5.03亿美元的额外付款，以及向Prolium收取销售净额的分层特许权使用费。该等付款取决于若干商业、临床开发及监管里程碑的达成。集团及诺诚健华集团亦将获得Prolium的少数股权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.